Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Beauty Health is back in focus as analysts trim their price target from US$1.65 to US$1.50, while a separate fair value estimate is reset from US$1.93 to US$1.69. The shift reflects fresh reactions to the Q4 report, where views are split between confidence in the FY26 EBITDA guidance and concerns around softer near term distributor trends and macro related pressures. In the sections that follow, you will see how these moving targets shape the evolving narrative around risk, reward, and what to watch next.
Stay updated as the Fair Value for Beauty Health shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Beauty Health.
-
TD Cowen highlights that Beauty Health’s FY26 EBITDA guidance sits roughly 20% above current Street expectations. This supports a view that management is aiming for meaningful profitability improvement over time.
-
Despite trimming its price target to US$1.50 from US$1.65, TD Cowen keeps a Hold rating. This signals that the firm still sees a case for staying engaged while monitoring how the guidance and execution line up.
-
TD Cowen’s lower price target reflects a reworked model after Q4, where revenue came in below the prior year but ahead of forecasts. The firm points to softer 1Q trends as distributors respond to macro pressure on ordering.
-
Recent coverage from Jefferies also comes with a Hold stance. Together with TD Cowen, this underlines a more cautious view on near term execution and the balance of risk and reward at current levels.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 2 risks for Beauty Health. See which could impact your investment.
-
Beauty Health issued first quarter guidance, calling for net sales between US$63 million and US$68 million.
-
For full year 2026, the company is guiding to net sales in a range of US$285 million to US$305 million and outlining the revenue scale it is targeting.
-
The company is promoting broader use of its Hydrafacial treatments paired with SkinStylus Nano-Channeling in U.S. aesthetic and wellness locations, and is positioning the protocol as a single session that combines exfoliation, serum delivery, and light therapy with no downtime.
-
A proposed settlement in a shareholder derivative action in Delaware would see Beauty Health implement or maintain certain corporate governance reforms, subject to court approval at a May 13, 2026 hearing.
-
Fair value is reduced from US$1.93 to US$1.69, a cut of roughly 13% in the modelled estimate of intrinsic value.
-
Revenue growth assumption is lowered from 4.00% to 2.30%.
-
Net profit margin assumption is reduced from 5.46% to 4.13%.
-
Future P/E assumption is raised from 19.41x to 23.48x.
-
Discount rate assumption edges up from 11.54% to 11.55%.
Narratives connect Beauty Health’s business story to analyst forecasts and an implied fair value, updating as new guidance, news, and risks emerge. They help you see how the moving pieces fit together rather than looking at any single data point in isolation.
Head over to the Simply Wall St Community and follow the Narrative on Beauty Health to stay up to date on:
-
How reliance on premium Hydrafacial treatments and devices shapes sensitivity to consumer trends and economic pressure on discretionary beauty spending.
-
The role of recurring consumables revenue, product launches, and an expanding global device base in supporting the long term earnings story.
-
Key risks from regulatory and sustainability demands, plus competition from larger beauty groups and indie brands pushing high tech and personalized skincare.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SKIN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
